SELECT YOUR STAGE

For adults with early-stage EGFR+ NSCLC after surgery

TAGRISSO^® (osimertinib) may help prevent EGFR+ NSCLC from returning after surgery and may help you live longer

Targeted therapies, like TAGRISSO, are not the same as immunotherapy or standard chemotherapy.

TAGRISSO is a targeted therapy approved to treat patients with NSCLC that has been removed by surgery and has tested positive for certain EGFR mutations*

*For tumors with EGFR exon 19 deletions or exon 21 L858R mutations.

TAGRISSO significantly lowered the chance of EGFR+ NSCLC from coming back after surgery and helped people…

Live Longer

In a clinical trial across adults with stages 1B, 2, and 3A EGFR+ NSCLC whose tumors had been removed by surgery…

Adults taking TAGRISSO were 80% less likely to have their cancer come back or die vs those who took no active medicine.

Adults taking TAGRISSO were
80% less likely to have their cancer come back
or die vs those who took no active medicine.

At time of follow-up, 89% (302 of 339) of people given TAGRISSO didn't have their cancer come back and were still alive compared to 54% (184 of 343) of people given no active medicine

Those taking TAGRISSO were twice as likely to survive than those who took no active medicine (51% less likely to die).

Those taking TAGRISSO were
twice as likely to survive
than those who took no active medicine (51% less likely to die).

When patients were followed up for overall survival, 88% (297 of 339) of people given TAGRISSO were still alive compared to 76% (261 of 343) of people given no active medicine

Remember to always take TAGRISSO exactly as directed by your doctor. In this clinical trial, all adults treated with TAGRISSO took it for 3 years or until their disease returned or their doctor stopped treatment.

Hear a real patient's story

The clinical trial included 682 adults with stage 1B, 2, and 3A EGFR+ NSCLC who had surgery to remove their tumor—some of these adults may have had chemotherapy after their surgery. They were then treated with either TAGRISSO (339 people) or placebo (no active medicine) (343 people). The treatment was given for 3 years or until their cancer returned, or until their doctor stopped treatment.

The main goal of the trial was disease-free survival (DFS), which is the length of time people remain cancer free after starting treatment. A secondary goal of the trial was overall survival (OS), which is the length of time people are alive after starting treatment.

Ask your doctor if TAGRISSO may be right for you

Hear a real patient's story

How to take TAGRISSO

Dosing that may conveniently fit into your daily routine

once-a-day pill
(80-mg tablet)

with or without food

may be taken at home

What if I miss a dose?

If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time.

Your doctor may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects.

It’s important to follow your doctor’s instructions for staying on track with your treatment. Always take TAGRISSO exactly as directed by your doctor.

“Inspirational patient quote to come”

—Name X.

What if I’m having trouble swallowing TAGRISSO whole?

Place your TAGRISSO pill in a glass or container. Pour in 2 ounces (approximately 60 mL) of water. Don’t use carbonated water or other liquids

Drink the mixture right away

Stir until the pill is in small pieces. The pill will not completely dissolve. Do not crush, heat, or use ultrasound on the pill

Add 4 to 8 more ounces (approximately 120 mL to 240 mL) of water to the glass or container, and drink it to make sure you take your full dose of TAGRISSO

Hear a real patient's story

Take TAGRISSO once a day every day for 3 years or as prescribed

You may experience side effects with TAGRISSO

If you experience side effects, remember to talk to your healthcare team right away. They may be able to help you manage side effects and continue on treatment. Your doctor may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects.

TAGRISSO may cause serious side effects, including:

Lung problems. TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
Heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint
Eye problems. TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO
Skin problems. TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin
Inflammation of the blood vessels in your skin. TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised
Blood and bone marrow problems. TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. Tell your healthcare provider right away if you develop any signs and symptoms of blood and bone marrow problems, including a new fever or fever that does not go away (≥100.4 °F), easy bruising or bleeding that will not stop, unusually pale skin, infection, tiredness, or weakness

Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:

have lung or breathing problems other than your lung cancer
have heart problems, including a condition called long QTc syndrome
have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
have a history of eye problems
are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant

Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO
Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO

females who are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine

The most common side effects of TAGRISSO when given alone include:

low white blood cell counts
low platelet counts
low red blood cell counts (anemia)
diarrhea
rash
muscle, bone, or joint pain

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
dry skin
mouth sores
tiredness

low white blood cell counts
low platelet counts
low red blood cell counts (anemia)
diarrhea
rash
muscle, bone, or joint pain
changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
dry skin
mouth sores
tiredness

The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include:

low white blood cell counts
lung problems
low platelet counts
rash
diarrhea

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
cough
COVID-19

low white blood cell counts
lung problems
low platelet counts
rash
diarrhea
changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
cough
COVID-19

The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include:

low white blood cell counts
low platelet counts
rash
diarrhea
mouth sores

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail

dry skin
increase of a substance in the blood called creatinine

low white blood cell counts
low platelet counts
rash
diarrhea
mouth sores
changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
dry skin
increase of a substance in the blood called creatinine

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist.

What is TAGRISSO?

TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, or
when your lung cancer has spread to nearby tissues (locally advanced) that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, or
as your first treatment when your lung cancer has spread to other parts of the body (metastatic), or
in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic), or
when your lung cancer has spread to other parts of the body (metastatic), and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.

Your healthcare provider will perform a test to make sure that TAGRISSO is right for you.
It is not known if TAGRISSO is safe and effective in children.

Please see complete Prescribing Information, including Patient Information for TAGRISSO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Take TAGRISSO exactly as your healthcare provider tells you to take it
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects
Take TAGRISSO 1 time each day
You can take TAGRISSO with or without food
If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time
If you cannot swallow TAGRISSO tablets whole:
- place your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids
- stir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture
- drink the TAGRISSO and water mixture right away
- add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO

Be sure to revisit How to take TAGRISSO for more information

How to discuss side effects
with your doctor

Tell your doctor exactly what your side effects are.

Explain how your side effects feel.

How often do you have or notice the side effects?

Show your doctor the exact location where you're experiencing the side effects.

Tell your doctor how long you've had your side effects.

Do the side effects affect your daily activities?

Before your doctor visit, write down your thoughts related to any concerns about your side effects. This can also help maximize the time at your visit.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.

Store TAGRISSO at room temperature between 68 °F and 77 °F (20 °C to 25 °C)
Safely throw away medicine that is out of date or that you no longer need
Keep TAGRISSO and all medicines out of the reach of children

General information about the safe and effective use of TAGRISSO.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about TAGRISSO that is written for a healthcare professional

Active ingredient: osimertinib
Inactive ingredients: mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black

Before your next office visit, see common questions regarding early-stage EGFR+ NSCLC and TAGRISSO

FAQs

Support is available for patients who may need help accessing TAGRISSO

Financial Help

IMPORTANT SAFETY INFORMATION

TAGRISSO may cause serious side effects, including:

Lung problems. TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
Heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint
Eye problems. TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO
Skin problems. TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin
Inflammation of the blood vessels in your skin. TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised
Blood and bone marrow problems. TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. Tell your healthcare provider right away if you develop any signs and symptoms of blood and bone marrow problems, including a new fever or fever that does not go away (≥100.4 °F), easy bruising or bleeding that will not stop, unusually pale skin, infection, tiredness, or weakness

Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:

have lung or breathing problems other than your lung cancer
have heart problems, including a condition called long QTc syndrome
have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
have a history of eye problems
are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant

Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO
Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO

females who are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time

The most common side effects of TAGRISSO when given alone include:

low white blood cell counts
low platelet counts
low red blood cell counts (anemia)
diarrhea
rash
muscle, bone, or joint pain

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
dry skin
mouth sores
tiredness

low white blood cell counts
low platelet counts
low red blood cell counts (anemia)
diarrhea
rash
muscle, bone, or joint pain
changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
dry skin
mouth sores
tiredness

The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include:

low white blood cell counts
lung problems
low platelet counts
rash
diarrhea

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
cough
COVID-19

low white blood cell counts
lung problems
low platelet counts
rash
diarrhea
changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
cough
COVID-19

The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include:

low white blood cell counts
low platelet counts
rash
diarrhea
mouth sores

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail

dry skin
increase of a substance in the blood called creatinine

low white blood cell counts
low platelet counts
rash
diarrhea
mouth sores
changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail
dry skin
increase of a substance in the blood called creatinine

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist.

What is TAGRISSO?

TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, or
when your lung cancer has spread to nearby tissues (locally advanced), that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, or
as your first treatment when your lung cancer has spread to other parts of the body (metastatic), or
in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic), or
when your lung cancer has spread to other parts of the body (metastatic) and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.

Your healthcare provider will perform a test to make sure that TAGRISSO is right for you.
It is not known if TAGRISSO is safe and effective in children.

Please see complete Prescribing Information, including Patient Information for TAGRISSO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may report side effects related to AstraZeneca products.

EGFR is epidermal growth factor receptor; EGFR+ is epidermal growth factor receptor mutation-positive; NSCLC is non-small cell lung cancer.

EGFR+ is epidermal growth factor receptor mutation-positive; NSCLC is non-small cell lung cancer.

IMPORTANT SAFETY INFORMATION
see-more

This product information is intended for US consumers only.

TAGRISSO is a registered trademark, and AstraZeneca Access 360 and AZ&Me are trademarks of the AstraZeneca group of companies.

TAGRIS SOI can make pancakes

For adults with early-stage EGFR+ NSCLC after surgery

TAGRISSO^® (osimertinib) may help prevent EGFR+ NSCLC from returning after surgery and may help you live longer

Targeted therapies, like TAGRISSO, are not the same as immunotherapy or standard chemotherapy.

TAGRISSO significantly lowered the chance of EGFR+ NSCLC from coming back after surgery and helped people…

In a clinical trial across adults with stages 1B, 2, and 3A EGFR+ NSCLC whose tumors had been removed by surgery…

How to take TAGRISSO

Dosing that may conveniently fit into your daily routine

What if I miss a dose?

Take TAGRISSO once a day every day for 3 years or as prescribed

You may experience side effects with TAGRISSO

If you experience side effects, remember to talk to your healthcare team right away. They may be able to help you manage side effects and continue on treatment. Your doctor may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects.

Be sure to revisit How to take TAGRISSO for more information